Results 231 to 240 of about 423,879 (287)
Some of the next articles are maybe not open access.
Arthritis & Rheumatology, 2022
ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +2 more sources
ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +2 more sources
Potential Dangers of Serum Urate-Lowering Therapy
The American Journal of Medicine, 2019In observational studies, high serum urate levels are associated with adverse outcomes, including mortality. However, the hypothesis that urate-lowering may improve nongout outcomes has not been confirmed by placebo-controlled clinical trials. On the contrary, 7 recent placebo-controlled trials of urate-lowering drugs with different mechanisms of ...
Maria Vanessa Perez-Gomez +5 more
openaire +2 more sources
Expert opinion on emerging urate-lowering therapies
Expert Opinion on Emerging Drugs, 2018There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate ...
Lisa K, Stamp +2 more
openaire +2 more sources
Psychology, Health & Medicine, 2023
This study aims to assess urate-lowering therapy adherence and the relationship with medication beliefs, self-efficacy, depression, anxiety, and COVID−19 pandemic-related concerns in Chinese gout patients during the COVID−19 outbreak.
R. Yin +5 more
semanticscholar +1 more source
This study aims to assess urate-lowering therapy adherence and the relationship with medication beliefs, self-efficacy, depression, anxiety, and COVID−19 pandemic-related concerns in Chinese gout patients during the COVID−19 outbreak.
R. Yin +5 more
semanticscholar +1 more source
Urate‐Lowering Therapy for Gout: Focus on Febuxostat
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010Gout is a common, painful, and often debilitating rheumatologic disorder that remains one of the few arthritic conditions that can be diagnosed with certainty and cured with appropriate therapy. Allopurinol is the most frequently prescribed agent for gout in the United States.
Bryan L, Love +3 more
openaire +2 more sources
International Journal of Rheumatic Diseases, 2023
We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first‐line urate‐lowering therapy (ULT) in patients with gout.
M. So, A. Kim, Seung-Geun Lee
semanticscholar +1 more source
We investigated the appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors (XOIs) as first‐line urate‐lowering therapy (ULT) in patients with gout.
M. So, A. Kim, Seung-Geun Lee
semanticscholar +1 more source
Urate-Lowering Therapy and Chronic Kidney Disease Progression
New England Journal of Medicine, 2020The prevalence and severity of chronic kidney disease (CKD) has been increasing for decades. Because of its tremendous financial and health burden, both to persons and to health systems, mitigation...
openaire +2 more sources
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution
Seminars in Arthritis and Rheumatism, 2017The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended.
Stamp, L, Dalbeth, Nicola
openaire +3 more sources
2016
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
openaire +1 more source
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
openaire +1 more source
[Gout: an overview of available urate lowering therapies].
Annales pharmaceutiques francaises, 2012The aim of urate-lowering therapy is to maintain urate concentration below the saturation point for monosodium urate. This therapy dissolves crystal deposits and cures gout while it is maintained. EULAR guidelines recommend that plasma urate should be maintained at a concentration less than 360μM, and the British Guidelines less than 300μM.
openaire +2 more sources